Table 1 Baseline clinical characteristics of study subjects
Variables | Conventional therapy (n = 112) | UI-EWD therapy (n = 55) | P-value |
|---|---|---|---|
Age (year)§ | 74 (39–88) | 64 (25–89) | 0.181 |
Sex (male)§ | 66 (58.9) | 32 (58.2) | 0.875 |
Medication, n (%) | |||
Anticoagulant | 9 (8.0) | 3 (5.5) | 0.753+ |
Antiplatelet agent | 32 (28.6) | 9 (16.4) | 0.085 |
Anticoagulant and antiplatelet agent | 11 (9.8) | 5 (9.1) | 0.549+ |
White blood cell (1000/μL) § | 6580 (2100–20,570) | 7270 (2290–36,410) | 0.337 |
Hb (g/dL)§ | 10.0 (12.0–4.9) | 12.4 (6.4–16.0) | 0.369 |
Platelet count (1000/μL)§ | 208 (55–654) | 222 (49–371) | 0.550 |
PTs (INR)§ | 1.03 (0.84–5.18) | 1.05 (0.84–18.40) | 0.320 |
aPTT (s)§ | 36.5 (24.2–79.2) | 36.3 (26.2–79.2) | 0.457 |
BUN (mg/dL)§ | 16.4 (5.5–139.8) | 15.5 (6.5–95.3) | 0.372 |
Cr (mg/dL)§ | 0.87 (0.29–8.43) | 0.83 (0.29–7.28) | 0.502 |
CCI ≥ 6, n (%) | 46 (41.4) | 39 (70.9) | 0.048 |
Follow-up duration (day)§ | 131 (7–668) | 47 (7–797) | 0.674 |